This chapter examines the application of germline and somatic genomic profiling to the diagnosis, risk stratification, and treatment selection in prostate cancer, with particular focus on BRCA1/2, ATM, and homologous recombination repair gene alterations. It reviews the clinical utility of liquid biopsy, circulating tumor DNA, and polygenic risk scores in contemporary practice. The integration of multi-omics platforms, proteomics, and transcriptomics into precision oncology frameworks for prostate cancer is discussed in detail.
Reviews
There are no reviews yet.